CO2023006691A2 - Polipéptidos de reclutamiento de células t basados en la reactividad de tcr alfa/beta - Google Patents

Polipéptidos de reclutamiento de células t basados en la reactividad de tcr alfa/beta

Info

Publication number
CO2023006691A2
CO2023006691A2 CONC2023/0006691A CO2023006691A CO2023006691A2 CO 2023006691 A2 CO2023006691 A2 CO 2023006691A2 CO 2023006691 A CO2023006691 A CO 2023006691A CO 2023006691 A2 CO2023006691 A2 CO 2023006691A2
Authority
CO
Colombia
Prior art keywords
cell recruitment
tcr alpha
polypeptides based
reactivity
beta
Prior art date
Application number
CONC2023/0006691A
Other languages
English (en)
Inventor
Katrijn Neyt
Annelies Roobrouck
Stephanie Staelens
Belle Tom Van
Judith Verhelst
Hoorick Diane Van
Original Assignee
Sanofi Sa
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ablynx Nv filed Critical Sanofi Sa
Publication of CO2023006691A2 publication Critical patent/CO2023006691A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente tecnología proporciona polipéptidos de reclutamiento de células T que se unen específicamente al dominio constante de un TCR humano y de primate no humano. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones. Los polipéptidos se pueden usar en métodos para el tratamiento del cáncer.
CONC2023/0006691A 2020-12-18 2023-05-23 Polipéptidos de reclutamiento de células t basados en la reactividad de tcr alfa/beta CO2023006691A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20306608 2020-12-18
EP2021086556 2021-12-17
EP21306822 2021-12-17
PCT/EP2021/086843 WO2022129637A1 (en) 2020-12-18 2021-12-20 T cell recruiting polypeptides based on tcr alpha/beta reactivity

Publications (1)

Publication Number Publication Date
CO2023006691A2 true CO2023006691A2 (es) 2023-05-29

Family

ID=79602034

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006691A CO2023006691A2 (es) 2020-12-18 2023-05-23 Polipéptidos de reclutamiento de células t basados en la reactividad de tcr alfa/beta

Country Status (10)

Country Link
US (1) US20240092919A1 (es)
EP (1) EP4263610A1 (es)
KR (1) KR20230122084A (es)
AU (1) AU2021402090A1 (es)
CA (1) CA3203141A1 (es)
CO (1) CO2023006691A2 (es)
IL (1) IL303740A (es)
MX (1) MX2023007299A (es)
TW (1) TW202241948A (es)
WO (1) WO2022129637A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342508A (zh) * 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
WO2023242247A1 (en) * 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
DK0702721T3 (da) 1993-06-09 2001-05-21 Unilever Nv Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
CA2321199A1 (en) 1998-02-19 1999-08-26 William A. Brady Compositions and methods for regulating lymphocyte activation
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
US7958021B2 (en) 2002-09-10 2011-06-07 Igt Method and device for collecting and reporting data
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
EP3279214A1 (en) 2010-10-29 2018-02-07 Ablynx NV Method for the production of immunoglobulin single variable domains
CN108659121A (zh) 2011-06-23 2018-10-16 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
AU2012271974B2 (en) 2011-06-23 2017-01-12 Ablynx Nv Serum albumin binding proteins
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
LT3294768T (lt) 2015-05-13 2019-11-11 Ablynx Nv T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
CA3005061A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
CN108473564B (zh) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
EP3541846A1 (en) 2016-11-16 2019-09-25 Ablynx NV T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
AU2017373746A1 (en) 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
MX2019008496A (es) 2017-01-17 2019-09-18 Ablynx Nv Aglutinantes de albumina serica mejorados.
SG11201906341XA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders

Also Published As

Publication number Publication date
WO2022129637A8 (en) 2023-08-10
MX2023007299A (es) 2023-07-04
AU2021402090A9 (en) 2024-05-16
IL303740A (en) 2023-08-01
CA3203141A1 (en) 2022-06-23
KR20230122084A (ko) 2023-08-22
US20240092919A1 (en) 2024-03-21
EP4263610A1 (en) 2023-10-25
AU2021402090A1 (en) 2023-08-03
TW202241948A (zh) 2022-11-01
WO2022129637A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CO2023006691A2 (es) Polipéptidos de reclutamiento de células t basados en la reactividad de tcr alfa/beta
PE20210287A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2019001567A1 (es) Anticuerpo conjugado que se une a la región constante del receptor de células t beta 1 (trbc1) o trbc2. (divisional solicitud 201803096)
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
AR109499A1 (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
NI201800057A (es) Anticuerpos anti-il1rap, moléculas de unión de antígeno biespecíficas que se unen a il1rap y cd3, y sus usos.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
AR117770A1 (es) Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112017003104A2 (pt) tratamento de câncer usando um receptor antigênico quimérico anti-cd123
UY33647A (es) ?agentes de unión a cd33?.
EP3611192A3 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
CL2020001607A1 (es) Anticuerpos anti alfa-sinucleína.
UY34905A (es) Proteínas de unión a il-1
CO2021006493A2 (es) Terapia del cáncer con células inmunitarias anti-liv1
CO7380754A2 (es) Antígenos asociados con enfermedad inflamantoria del intestino
CL2023002543A1 (es) Anticuerpos de unión a vista a ph ácido
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
CO2022017249A2 (es) Anticuerpos que se unen a cd3
CO2022002937A2 (es) Anticuerpos de unión a vista a ph ácido
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CL2020002339A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores
BR112015031080A2 (pt) métodos para intensificar a conversão microbiana de biomassa celulósica com aumento mecânico